| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8224899 | International Journal of Radiation Oncology*Biology*Physics | 2012 | 7 Pages |
Abstract
SBRT is a safe and efficacious modality and appears to be well-tolerated at the dose fractionation we have used, and its use correlates with improved survival in this cohort of patients with recurrent unresectable HCC. Out-field recurrence is the major cause of failure. Further studies of combinations of SBRT and systemic therapies may be reasonable.
Keywords
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Wen-Yen M.D., Yee-Min M.D., Ph.D., Meei-Shyuan Ph.D., Li-Ping M.D., Ph.D., Chang-Ming M.D., Kai-Hsiung M.D., Kuen-Tze M.D., Jang-Chun M.D., Hsing-Lung M.D., Chun-Shu M.D., Yu-Fu M.D., Chao-Yueh M.D., Yao-Wen M.D.,